Abstract

Analysis of agonist-driven phosphorylation of G protein-coupled receptors (GPCRs) can provide valuable insights into the receptor activation state and ligand pharmacology. However, to date, assessment of GPCR phosphorylation using high-throughput applications has been challenging. We have developed and validated a bead-based immunoassay for the quantitative assessment of agonist-induced GPCR phosphorylation that can be performed entirely in multiwell cell culture plates. The assay involves immunoprecipitation of affinity-tagged receptors using magnetic beads followed by protein detection using phosphorylation state-specific and phosphorylation state-independent anti-GPCR antibodies. As proof of concept, five prototypical GPCRs (MOP, C5a1, D1, SST2, CB2) were treated with different agonizts and antagonists, and concentration-response curves were generated. We then extended our approach to establish selective cellular GPCR kinase (GRK) inhibitor assays, which led to the rapid identification of a selective GRK5/6 inhibitor (LDC8988) and a highly potent pan-GRK inhibitor (LDC9728). In conclusion, this versatile GPCR phosphorylation assay can be used extensively for ligand profiling and inhibitor screening.

A G protein-coupled receptors (GPCRs) phosphorylation assay for cell culture plates can be used for ligand profiling and inhibitor screening, as evidenced by the identification of two GRK inhibitor compounds.

Details

Title
A bead-based GPCR phosphorylation immunoassay for high-throughput ligand profiling and GRK inhibitor screening
Author
Kaufmann, Johanna 1 ; Blum, Nina Kathleen 1 ; Nagel, Falko 2 ; Schuler, Anna 3 ; Drube, Julia 4   VIAFID ORCID Logo  ; Degenhart, Carsten 5 ; Engel, Julian 5 ; Eickhoff, Jan Eicke 5 ; Dasgupta, Pooja 3 ; Fritzwanker, Sebastian 3 ; Guastadisegni, Maria 6 ; Schulte, Clemens 7 ; Miess-Tanneberg, Elke 3 ; Maric, Hans Michael 7   VIAFID ORCID Logo  ; Spetea, Mariana 6   VIAFID ORCID Logo  ; Kliewer, Andrea 3   VIAFID ORCID Logo  ; Baumann, Matthias 5 ; Klebl, Bert 5 ; Reinscheid, Rainer K. 3 ; Hoffmann, Carsten 4   VIAFID ORCID Logo  ; Schulz, Stefan 1   VIAFID ORCID Logo 

 Universitätsklinikum Jena, Institut für Pharmakologie und Toxikologie, Friedrich-Schiller-Universität Jena, Jena, Germany (GRID:grid.275559.9) (ISNI:0000 0000 8517 6224); 7TM Antibodies GmbH, Jena, Germany (GRID:grid.275559.9) 
 7TM Antibodies GmbH, Jena, Germany (GRID:grid.275559.9) 
 Universitätsklinikum Jena, Institut für Pharmakologie und Toxikologie, Friedrich-Schiller-Universität Jena, Jena, Germany (GRID:grid.275559.9) (ISNI:0000 0000 8517 6224) 
 Universitätsklinikum Jena, Institut für Molekulare Zellbiologie, CMB—Center for Molecular Biomedicine, Friedrich-Schiller-Universität Jena, Jena, Germany (GRID:grid.275559.9) (ISNI:0000 0000 8517 6224) 
 Lead Discovery Center GmbH, Dortmund, Germany (GRID:grid.505582.f) 
 University of Innsbruck, Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), Innsbruck, Austria (GRID:grid.5771.4) (ISNI:0000 0001 2151 8122) 
 University of Wuerzburg, Rudolf Virchow Center, Center for Integrative and Translational Bioimaging, Wuerzburg, Germany (GRID:grid.8379.5) (ISNI:0000 0001 1958 8658) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2734482040
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.